BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc.（BCRX）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · BCRX · 截至 2025年9月30日
股东结构概览
296
机构持有人数
▼ 13 vs Q2
$1.48B
机构持仓总市值
▼ $291.89M vs Q2
209.89M
总流通股
freeFloat 86.84%
194.20M
13F 申报持股数
▼ 3.03M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
BCRX 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC biological products, (no diagnostic substances) | 21.79M | 10.42% | 10.42% | $165.39B | Nov 7, 2025 | ▲ 1.25M |
BLACKROCK, INC. biological products, (no diagnostic substances) | 21.25M | 10.16% | 10.16% | $161.26B | Nov 12, 2025 | ▼ 180.0K |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) biological products, (no diagnostic substances) | 12.17M | 5.82% | 5.82% | $92.36B | Nov 14, 2025 | ▲ 7.48M |
STATE STREET CORP biological products, (no diagnostic substances) | 9.81M | 4.69% | 4.69% | $74.44B | Nov 14, 2025 | ▲ 1.30M |
KYNAM CAPITAL MANAGEMENT, LP biological products, (no diagnostic substances) | 9.39M | 4.49% | 4.49% | $71.27B | Nov 14, 2025 | ▲ 926.5K |
UBS GROUP AG biological products, (no diagnostic substances) | 5.97M | 2.85% | 2.85% | $45.30B | Nov 13, 2025 | ▲ 353.1K |
ALKEON CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 5.46M | 2.61% | 2.61% | $41.47B | Nov 14, 2025 | ▼ 250.0K |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP biological products, (no diagnostic substances) | 5.23M | 2.50% | 2.50% | $39.67B | Nov 13, 2025 | ▲ 947.4K |
MORGAN STANLEY biological products, (no diagnostic substances) | 5.20M | 2.49% | 2.49% | $39.49B | May 27, 2026 | ▼ 126.7K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 5.05M | 2.42% | 2.42% | $38.35B | Nov 12, 2025 | ▼ 2.3K |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
22
增持
+19.57M 股2
新建仓
首次建仓25
减持
−14.24M 股0
清仓
完全退出净股数变化（前50家）
+5.34M
+19.57M / −14.24M
净新增持仓人
-1
新建 2 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
BCRX 内幕交易记录
数据来源：SEC Form 4
近期内部人员以卖出为主。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
0
买入笔数
0
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Milne Jill C. director | May 29, 2026 | Award | 1,262 | $8.91 | $11.2K | 16.6K | Form 4 ↗ |
Stonehouse Jon P director | May 29, 2026 | Award | 631 | $8.91 | $5.6K | 1.32M | Form 4 ↗ |
McKee Amy E director | May 29, 2026 | Award | 631 | $8.91 | $5.6K | 31.9K | Form 4 ↗ |
MILANO VINCENT director | May 29, 2026 | Award | 1,122 | $8.91 | $10.0K | 93.2K | Form 4 ↗ |
Frank Steven director | May 29, 2026 | Award | 1,262 | $8.91 | $11.2K | 20.2K | Form 4 ↗ |
McKee Amy E director | May 18, 2026 | Sale | 11,180 | $8.97 | $100.3K | 31.3K | Form 4 ↗ |
Barnes Alane P Chief Legal Officer | May 13, 2026 | Sale | 62,500 | $9.54 | $596.3K | 400.7K | Form 4 ↗ |
Menon Sandeep Chief R&D Officer | Apr 6, 2026 | Award | 441,350 | $9.47 | $4.18M | 441.4K | Form 4 ↗ |
Menon Sandeep Chief R&D Officer | Apr 6, 2026 | Award | 205,150 | — | — | 205.2K | Form 4 ↗ |
HEGGIE THERESA director | Mar 20, 2026 | Sale | 49,933 | $10.11 | $504.8K | 65.4K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
BioCryst Pharmaceuticals, Inc.（BCRX）主要由机构投资者持有，机构持股比例约为 92.5%。公司内部人员持股约 13.16%，散户及公众持股约占剩余的 0.00%。
BioCryst Pharmaceuticals, Inc. 最大机构股东为 VANGUARD GROUP INC，截至 September 30, 2025 持有约 21.79 million 股，占总流通股的 10.42%。
目前共有 296 家机构持有 BCRX 股票，合计持仓市值约 $1.48 billion，数据来源为最新 SEC 13F 申报。
常见问题
BCRX ownershipBioCryst Pharmaceuticals, Inc.（BCRX）主要由机构投资者持有，机构持股约 92.5%。最大股东为 VANGUARD GROUP INC，持股比例 10.42%。内部人员持股约 13.16%。数据来源 SEC Form 13F，截至 September 30, 2025。